01 5Advate
02 5Kogenate/Kovaltry/ Jivi
03 2Recombinate
04 6Refacto AF/Xyntha
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Rare Disorders
Currency : USD
2019 Revenue in Millions : 426
2018 Revenue in Millions : 514
Growth (%) : -17
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Rare Disorders
Currency : USD
2020 Revenue in Millions : 1,029
2019 Revenue in Millions : 1,067
Growth (%) : -4
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Hematology
Currency : USD
2019 Revenue in Millions : 1,443
2018 Revenue in Millions : 0
Growth (%) : N/A
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Rare Disorders
Currency : USD
2020 Revenue in Millions : 370
2019 Revenue in Millions : 426
Growth (%) : -13
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Rare Disorders
Currency : USD
2021 Revenue in Millions : 906
2020 Revenue in Millions : 1,029
Growth (%) : -3
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 1,253
2019 Revenue in Millions : 1,473
Growth (%) : -15
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 1,019
2020 Revenue in Millions : 1,201
Growth (%) : -9
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Rare Disorders
Currency : USD
2021 Revenue in Millions : 304
2020 Revenue in Millions : 370
Growth (%) : -18
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 889
2021 Revenue in Millions : 906
Growth (%) : -2
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 935
2021 Revenue in Millions : 1,019
Growth (%) : -8
LOOKING FOR A SUPPLIER?